EPI Data Slicer
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Huntington’s disease (HD) patient populations covering 171…
Clarivate Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in the Middle East & Africa (Egypt, Nigeria, Saudi Arabia, and South…
Clarivate Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in the Asia-Pacific region (Hong Kong, Philippines, Taiwan, Thailand,…
Clarivate Epidemiology’s coverage of Huntington’s disease (HD) in Europe comprises epidemiological estimates of key patient populations in 12 major mature pharmaceutical markets (Austria, Belgium,…
Clarivate Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in the Americas (Argentina, Canada, Chile, Colombia, and Peru). We…
Clarivate Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in emerging markets (Brazil, Russia, India, China, Mexico, Turkey, and…
Clarivate Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in seven major mature pharmaceutical markets (the United States, France…
Clarivate Epidemiology’s coverage of HD comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the incidence of HD for each country, as well as…
Huntington’s disease (HD) is a rare progressive neurological disorder characterized by movement disorders, cognitive decline, behavioral changes, and psychiatric disturbances. Current treatment…